The role of NK cells in autoimmune disease

Autoimmunity

Volumn 35, Issue 1, 2002, Pages 1-14

  Baxter, Alan G ^a   Smyth, Mark J ^a  

^a Institute of Cancer Medicine and Cell Biology   (Australia)

Author keywords

Autoimmune disease; Diabetes; NK cells; Systemic lupus erythematosus

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA INTERFERON; BETA INTERFERON; CD161 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CD94 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; ROQUINIMEX; UNCLASSIFIED DRUG;

ARTHRITIS; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENCEPHALOMYELITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THYROID DISEASE; VIRUS HEPATITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; HYDROXYQUINOLINES; INTERFERONS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MULTIPLE SCLEROSIS; RATS; SELF TOLERANCE;

EID: 0036082290     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930290005864     Document Type: Review

References (186)

1. Development of human T and natural killer cells
2. Development of self-recognition systems in natural killer cells
3. Differentiation of NK1.1+, Ly49+NK cells from flt3+ multipotent marrow progenitor cells
4. NK cells and apoptosis
5. CTL granules: Evolution of vesicles essential for combating virus infections
6. The role of natural killer cells in immune surveillance of cancer
7. The immuno-regulatory effects of NK cells: The role of TGF-beta and implications for autoimmunity
8. Regulation of adaptive immunity by natural killer cells
9. Biology of natural killer cells
10. NK cells receptors
11. Receptors for HLA class-I molecules in human natural killer cells
12. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits
13. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)
14. Fetal and neonatal NK1.1+Ly-49-cells can distinguish between major histocompatibility complex class I(hi) and class I(lo) target cells: Evidence for a Ly-49-independent negative signaling receptor
15. Acquisition of Ly49 receptor expression by developing natural killer cells
16. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
17. In search of the missing self: MHC molecules and NK cell recognition
18. Transplantable NK cell progenitors in murine bone marrow
19. Identification of pro-thymocytes in murine fetal blood: T lineage commitment can precede thymus colonization
20. Requirement for the thymus in alphabeta T lymphocyte lineage commitment
21. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells
22. Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells
23. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells
24. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
25. Hematopoietic cells and radioresistant host elements influence natural killer cell differentiation
26. Host MHC class I molecules modulate in vivo expression of a NK cell receptor
27. Immune responses in interleukin-2-deficient mice
28. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain
29. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain
30. Interleukin (I.L.)15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor
31. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice I. Characterization of natural killer cell induction
32. Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection
33. Activation and function of natural killer cell responses during viral infections
34. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver
35. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow
36. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways
37. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration
38. An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections
39. MHC class I alloantigen specificity of Ly-49+IL-2-activated natural killer cells
40. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells
41. The Ly-49D receptor activates murine natural killer cells
42. Inhibitory MHC class I receptors on NK cells and T cells
43. Immuno-receptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
44. LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase
45. An activating immuno-receptor complex formed by NKG2D and DAP10
46. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice
47. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells
48. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA
49. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages
50. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB
51. Missing self recognition by natural killer cells in MHC class I transgenic mice. A receptor calibration model for how effector cells adapt to self
52. Killer cell receptors: Keeping pace with MHC class I evolution
53. Development and tolerance of natural killer cells
54. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice
55. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: Non-responsiveness controlled by beta 2m- bone marrow in chimeric mice
56. Natural killer function is systemic lupus erythematosus
57. Natural killing in systemic lupus erythematosus: Inhibitory effects of serum
58. Natural cell mediated cytotoxicity in systemic lupus erythematosus
59. Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus
60. Natural killer cells and interferon responses in patients with systemic lupus erythematosus
61. Abnormal natural killer cell activity in systemic lupus erythematosus: An intrinsic defect in the lytic event
62. Natural and antibody-dependent cellular cytotoxicity in children with systemic lupus erythematosus and juvenile dermatomyositis
63. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation
64. Natural killer cells in systemic lupus erythematosus
65. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus
66. Lack of NK cells in lupus patients with renal involvement
67. Alternative membrane forms of FcgRIII (CD16) on human NK cells and neutophils. Cell type specific expression of two genes which differ in single nucleotide substitutions
68. A triallelic Fcg receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcgRIIA
69. Binding of monomeric IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells
70. A novel polymorphism of FcγRIII (CD16) alters receptor function and predisposes to autoimmune disease
71. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families
72. Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees
73. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II)
74. Altered natural killer and natural cytotoxic cellular activities in lpr mice
75. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells
76. High hepatic natural killer cell activity in murine lupus
77. Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice
78. Characterization and specificity of B-cell responses in lupus induced by Mycobacterium bovis in NOD/Lt mice
79. Immunologic aspects of the non-obese diabetic (NOD) mouse. Abnormalities of cellular immunity
80. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice
81. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice
82. Linkage analysis of systemic lupus erythematosus induced in diabetes-prone nonobese diabetic mice by Mycobacterium bovis
83. Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenic factor
84. The effect of recombinant alpha2-interferon on defective natural killer cell activity in multiple sclerosis
85. Natural cytotoxic activity in multiple sclerosis patients: Defects in IL-2/interferon gamma-regulatory circuit
86. Progressive multiple sclerosis: Abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations
87. Natural killer activity of peripheral blood mononuclear cells from patients with various forms of lupus erythematosus
88. A role for natural killer cells in the immunopathogenesis of multiple sclerosis
89. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis
90. Natural killer cell activity in multiple sclerosis
91. Natural killer cell activity in patients with multiple sclerosis given alpha interferon
92. Decreased N.K. killing in patients with multiple sclerosis: An analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of disease
93. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis
94. Genetic influence on natural cytotoxicity and interferon production in multiple sclerosis studies in monozygotic discordant twins
95. A study of some immunological variables in twins, doscordant for multiple sclerosis
96. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon
97. Natural killer cell number and activity in multiple sclerosis
98. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls
99. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls
100. Natural killer cells and lymphocyte subsets in active MS and acture inflammation of the C.N.S.
101. Regulation of experimental autoimmune encephalomylitis by natural killer (NK) cells
102. Role of natural killer cells and TCRgd T cells in acute autoimmune encephalomyelitis
103. Prospective study of lymphocyte subsets in subjects genetically susceptible to type 1 (insulin dependent) diabetes
104. Two monoclonal antibodies (H25 and H366) defined cells with K/NK activity
105. Alterations in lymphocyte subpopulations in type 1 (insulin dependent) diabetes mellitus: Exploration of possible mechanisms and relationships to autoimmune phenomena
106. Immunoregulatory dysfunctions in type 1 diabetes: Natural and antibody-dependent cellular cytotoxic activities
107. Natural killer and islet killer cell activities in type 1 (insulin dependent) diabetes
108. Cell-mediated immunity and biological response modifiers in insulin-dependent diabetes mellitus complicated by end-stage renal disease
109. Deficiency of phenotypic cytotoxic-suppressor T lymphocytes in the BB/W rat
110. Natural killer cell number and function in the spontaneously diabetic BB/W rat
111. Prevention of diabetes in Biobreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells
112. Prevention of recurrent autoimmune diabetes in BB rats by anti-asialo-GM1 antibody
113. Poly I:C induces development of diabetes mellitus in BB rat
114. Immunological responses of the BB rat colony in Edinburgh
115. CD8+ T-cells are required for adoptive transfer of the BB rat diabetic syndrome
116. Natural killer cell depletion and diabetes mellitus in the BB/Wor rat
117. The role of NK cell activity in the pathogenesis of poly I:C accelerated and spontaneous diabetes in the diabetes prone BB rat
118. Differential expression of the ASGM1 antigen on anti-virus and alloreactive cytotoxic T lymphocytes
119. Regulation of natural killer progenitors: Studies with a novel immunomodulator with distinct effects at the precursor level
120. Phase I. Study in malignancy of LS2616, a new immunomodulator
121. Rat cardiac allografts protected with cyclosporin A are rejected in the presence of LS-2616
122. Abolition of the effect of cyclosporin on rat cardiac allograft rejection by the new immunomodulator LS-2616
123. The quinoloine-3-carboxamide linomide inhibits angiogenesis in vivo
124. Effects of immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma
125. A treatment for metastasis of murine ocular melanoma
126. Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers
127. An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma
128. EORTC phase II study of daily oral Linomide in metastatic renal cell carcinoma patients with good prognostic factors
129. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice
130. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice
131. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator
132. Decreased levels of pathogenic IgG anti-DNA antibodies after linomide treatment
133. Modulation of experimental systemic lupus erythematosus with linomide
134. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide
135. Treatment of chronic relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide)
136. Linomide, a new treatment for autoimmune disease: The potential in type 1 diabetes
137. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug
138. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide
139. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
140. Low dose linomide in type 1 juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial
141. Linomide in relapsing and secondary progressive MS; Part II - MRI results
142. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase III trials
143. Linomide in relapsing and secondary preogressive MS: Part I - Trial design and clinical results
144. Lessons from Linomide; A failed trial but not a failure
145. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons
146. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons
147. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis
148. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis
149. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis
150. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats
151. Interferon-gamma confers resistance to experimental allergic encephalomyelitis
152. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse
153. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis
154. Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains
155. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-gamma
156. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis
157. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
158. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis
159. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis (parts I and II)
160. Interferon beta-1b in the treatment of multiple sclerosis
161. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
162. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
163. Multiple sclerosis
164. Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon beta-1B
165. Autoimmune hyperthyroidism inpatients with multiple sclerosis treated with interferon beta-1b
166. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis
167. Autoimmune thyroid dysfunction in hematologic malignancies treated with alpha-interferon
168. Side effects of high-dose interferon therapy for chronic hepatitis
169. Association of MS with thyroid disorders
170. Autoimmune events during interferon beta-1b treatment for multiple sclerosis
171. Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats
172. α-Interferon inhibits the development of diabetes in NOD mice
173. Remissions in newly diagnosed Type 1 (insulin-dependent) diabetes: Influence of interferon as an adjunct to insulin therapy
174. Systemic lupus erythematosus after a-interferon therapy for chronic hepatitis c: A case report and review of the literature
175. Occurrence of IDDM during interferon therapy for chronic viral hepatitis
176. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis
177. Onset of diabetes with high titre anti-GAD antibody after IFN therapy for chronic hepatitis
178. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis
179. Autoimmune endocrine disease induced by recombinant interferon-a therapy for chronic active type C hepatitis
180. Interferon-a therapy may induce insulin autoantibody development in patients with chronic viral hepatitis
181. Caution is required with interferon a as a potential treatment for type 1 diabetes
182. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
183. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
184. Perforin protects against autoimmunity in lupus-prone mice
185. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalitis
186. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response